Lit­tle Cona­tus' No­var­tis-part­nered liv­er drug suf­fers third straight de­feat, but CEO Men­to is still hold­ing out hope

Lit­tle Cona­tus’ No­var­tis-part­nered liv­er drug is one step clos­er to the scrap heap, with its third mid-stage fail­ure.

The Swiss drug­mak­er hand­ed the San Diego-based biotech $50 mil­lion up­front and an in­jec­tion of con­fi­dence in late 2016 to li­cense the drug, em­ri­c­as­an. Since then, it has flopped in a tri­fec­ta of stud­ies. An­oth­er Phase II study is ex­pect­ed to read­out lat­er this year.

Steven Men­to

The 318-pa­tient tri­al, dubbed EN­CORE-NF, was test­ing two dos­es (5 mg, 50 mg) of the drug against a place­bo in biop­sy-con­firmed NASH and liv­er fi­bro­sis pa­tients. Em­ri­c­as­an missed the pri­ma­ry end­point of im­prov­ing fi­bro­sis by ≥1 on the val­i­dat­ed Clin­i­cal Re­search Net­work (CRN) stage sys­tem, with no wors­en­ing of steato­hep­ati­tis com­pared to place­bo at week 72, the com­pa­ny said late Thurs­day.

In a sep­a­rate fil­ing, Cona­tus pro­vid­ed a lit­tle more tri­al de­tail. The re­sponse rates in the 5 mg em­ri­c­as­an, 50 mg em­ri­c­as­an and place­bo treat­ment groups were 11.2%, 12.3% and 19.0%, re­spec­tive­ly. Sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tions were ob­served in ALT (el­e­vat­ed lev­els of this en­zyme in­di­cates a liv­er in dis­tress) and Cas­pase 3/7 (en­zymes that play es­sen­tial roles in pro­grammed cell death) in the 5 mg and 50 mg em­ri­c­as­an treat­ment groups.

The com­pa­ny’s shares $CNAT more than halved pre-mar­ket on Fri­day to $1.43.

Akin to the pre­vi­ous fail­ures, Cona­tus’ CEO played it cool, sug­gest­ing the drug could still work in pa­tients with NASH, which is typ­i­cal­ly as­so­ci­at­ed with obe­si­ty and di­a­betes and is set to eclipse he­pati­tis C as the lead­ing rea­son for liv­er trans­plants by 2020.

“Al­though em­ri­c­as­an did not have the de­sired ef­fect in these ear­li­er-stage NASH fi­bro­sis pa­tients, we be­lieve its demon­strat­ed bio­mark­er ac­tiv­i­ty across a broad spec­trum of liv­er dis­ease war­rants con­tin­ued eval­u­a­tion in more ad­vanced-stage NASH cir­rho­sis pa­tients,” chief Steven Men­to said in a state­ment, adding that the com­pa­ny would await ad­di­tion­al da­ta read­outs lat­er this year be­fore de­ter­min­ing the next steps for the em­ri­c­as­an pro­gram with No­var­tis.

Stifel’s Stephen Wil­ley did not buy what Cona­tus was sell­ing. “The fail­ure…fur­ther lim­its our abil­i­ty to gen­er­ate any lin­ger­ing en­thu­si­asm for re­main­ing full year 2019 mile­stones.”

“The lim­it­ed ef­fi­ca­cy de­tails pro­vid­ed by man­age­ment ac­tu­al­ly sug­gest­ed a di­rec­tion­al detri­ment in em­ri­c­as­an-treat­ed pa­tients…the lack of any clin­i­cal con­se­quences as­so­ci­at­ed with these ben­e­fits is con­sis­tent with every oth­er em­ri­c­as­an study re­port­ed to date.”

Last April, em­ri­c­as­an failed its first Phase II tri­al, in­volv­ing liv­er trans­plant pa­tients with fi­bro­sis or cir­rho­sis. In De­cem­ber, the drug failed to im­press in a sec­ond study (dubbed EN­CORE-PH), in­volv­ing NASH cir­rho­sis pa­tients — whose liv­ers were cop­ing with the dam­age and still able to per­form im­por­tant func­tions, but were at high risk for de­com­pen­sa­tion.

Wil­ley pre­dict­ed the Phase IIb EN­CORE-LF tri­al, slat­ed for read­out in mid-2019 and in­volv­ing de­com­pen­sat­ed NASH pa­tients, is al­so doomed to fail, giv­en that the 5/25mg em­ri­c­as­an dos­es giv­en in EN­CORE-PH ac­tu­al­ly re­sult­ed in wors­en­ing of symp­toms in pa­tients with base­line de­com­pen­sat­ed cir­rho­sis.

“(T)he on­ly em­ri­c­as­an dose with­in EN­CORE-PH to sug­gest an in­cre­men­tal ben­e­fit in de­com­pen­sat­ed pa­tients was the 50mg dose – which isn’t even be­ing eval­u­at­ed in EN­CORE-LF. We al­so be­lieve EN­CORE-LF-el­i­gi­ble pa­tients rep­re­sent a very dif­fi­cult-to-treat pop­u­la­tion of pa­tients in whom the na­ture and rate of events are of­ten both dif­fi­cult to pre­dict and un­cor­re­lat­ed to sup­port­ive care ther­a­py – mak­ing the achieve­ment of a sta­tis­ti­cal win in this set­ting an even more-chal­leng­ing en­deav­or.”

NASH — char­ac­ter­ized by a buildup of ex­cess fat in the liv­er that in­duces chron­ic in­flam­ma­tion and even­tu­al­ly cul­mi­nates in scar­ring that can lead to cir­rho­sis, liv­er fail­ure, can­cer and death — is a high risk-re­ward dis­ease that has at­tract­ed a pletho­ra of drug­mak­ers big and small, and re­searchers ex­pect it will take a cock­tail of new drugs to tru­ly de­feat the dis­ease.

In­ter­cept $ICPT in Feb­ru­ary re­port­ed that a piv­otal late-stage study test­ing its OCA treat­ment hit a high­ly sta­tis­ti­cal­ly sig­nif­i­cant score on an im­prove­ment in liv­er fi­bro­sis with­out any wors­en­ing of NASH, but missed the end­point for NASH res­o­lu­tion with­out wors­en­ing of fi­bro­sis. Gilead $GILD, mean­while, ex­pe­ri­enced a ma­jor set­back af­ter its NASH drug selon­sert­ib failed its Phase III. France’s Gen­fit is ex­pect­ed to of­fer its key NASH read­out lat­er this year.

Janet Woodcock (Greg Nash/Pool via AP Images)

'I re­al­ly don’t look back': Janet Wood­cock on her tran­si­tion away from drugs

Janet Woodcock may have one of the most historically long and drug-intense tenures in FDA history, but her new role is outside of all things pharma and the once-acting FDA commissioner isn’t looking back.

“No I really don’t look back,” Woodcock told Endpoints News via email on Monday morning. “Yes I will be transitioning. Longer discussion on infrastructure needed.”

An NYU surgeon transplants an engineered pig kidney into the outside of a brain-dead patient (Joe Carrotta/NYU Langone Health)

'Xeno­trans­plan­ta­tion is com­ing': New NE­JM pa­per gives de­tailed look in­to 2 pig-to-hu­man kid­ney trans­plant cas­es

The thymokidney is a curious organ, if you could call it that. It’s a sort of Frankensteinian creation — a system of pig thymus embedded underneath the outer layer of a pig’s kidney, made for human transplantation.

In the first case of pig-to-human xenotransplantation of a kidney into a brain-dead patient, the thymokidney quietly featured front and center.

In that experiment, which took place in September of last year, NYU researchers led by Robert Montgomery sutured a pig thymokidney onto the leg of a brain-dead 66-year-old woman. That case was widely reported on by a horde of major media outlets, including the New York Times, the BBC, and an in-depth feature by USA Today.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric, Biohaven CEO

UP­DAT­ED: Fresh off $11.6B sale to Pfiz­er, New Bio­haven hits Phase III set­back just weeks af­ter Vlad Coric chalked up promise

When Pfizer bought up Biohaven’s migraine portfolio in the largest M&A deal of the year earlier this month, Biohaven CEO Vlad Coric promised the rest of the pipeline, which will live on under the umbrella of New Biohaven, still has a lot to offer. But that vision took a dent Monday as the drugmaker revealed it’s once again flopped on troriluzole.

The glutamate regulator failed to meet the primary endpoint on a Phase III study in patients with spinocerebellar ataxia, an inherited disorder that impairs a person’s ability to walk, speak and swallow. SCA can also lead to premature death.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Bay­er sounds re­treat from a $670 mil­lion CAR-T pact in the wake of a pa­tient death

Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the watchful eye of the FDA, its Big Pharma partners at Bayer are bowing out of a $670 million global alliance. And the move is forcing a revamp of Atara’s pipeline plans, even as research execs vow to continue work on the two drugs allied with Bayer 18 months ago, which delivered a $60 million cash upfront.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Co­pay coupons gone wrong, again: Pfiz­er pays al­most $300K to set­tle com­plaints in four states

Pfizer has agreed to pay $290,000 to settle allegations of questionable copay coupon practices in Arizona, Colorado, Kansas, and Vermont from 2014 to 2018.

While the company has not admitted any wrongdoing as part of the settlement, Pfizer has agreed to issue restitution checks to about 5,000 consumers.

A Pfizer spokesperson said the company has “enhanced its co-pay coupons to alleviate the concerns raised by states and agreed to a $30,000 payment to each.”

Delaware court rules against Gilead and Astel­las in years-long patent case

A judge in Delaware has ruled against Astellas Pharma and Gilead in a long-running patent case over Pfizer-onwed Hospira’s generic version of Lexiscan.

The case kicked off in 2018, after Hospira submitted an Abbreviated New Drug Application (ANDA) for approval to market a generic version of Gilead’s Lexiscan. The drug is used in myocardial perfusion imaging (MPI), a type of nuclear stress test.

Taye Diggs (courtesy Idorsia)

Idor­sia inks an­oth­er celebri­ty en­dors­er deal with ac­tor and dad Taye Dig­gs as Qu­viviq in­som­nia am­bas­sador

Idorsia’s latest Quviviq insomnia campaign details the relatable dad story of a well-known celebrity — actor and Broadway star Taye Diggs.

Diggs stopped sleeping well after the birth of his son, now more than 10 years ago. Switching mom-and-dad nightly shifts to take care of a baby interrupted his sleep patterns and led to insomnia.

“When you’re lucky enough to be living out your dream and doing what you want, but because of something as simple as a lack of sleep, you’re unable to do that, it felt absolutely — it was treacherous,” he says in an interview-style video on the Quviviq website.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Belén Garijo, Merck KGaA CEO (Kevin Wolf/AP Images for EMD Serono)

Mer­ck KGaA pumps €440M in­to ex­pand­ing and con­struct­ing Irish man­u­fac­tur­ing fa­cil­i­ties

The area of Ireland famous for Blarney Castle and its cliffsides along the Atlantic Ocean is seeing Merck KGaA expand its commitment there.

The German drug manufacturer is expanding its membrane and filtration manufacturing capabilities in Ireland. The company will invest approximately €440 million ($470 million) to increase membrane manufacturing capacity in Carrigtwohill, Ireland, and build a new manufacturing facility at Blarney Business Park, in County Cork, Ireland.

Rep. Katie Porter (D-CA) (Michael Brochstein/Sipa USA/Sipa via AP Images)

House Dems to Sen­ate lead­er­ship: Quick­ly move a rec­on­cil­i­a­tion bill with drug price ne­go­ti­a­tion re­forms

Twenty House Democrats, including Reps. Katie Porter of California and Susan Wild of Pennsylvania, are calling on Senate leaders to move quickly with a reconciliation bill (meaning they only need a simple majority for passage) with prescription drug pricing reforms, and to include adding new authority for Medicare to negotiate drug prices.

They also called on the Senate to specifically follow suit with the House passage of a $35 per month insulin cap (as Senate Majority Leader Chuck Schumer’s deadline for a vote on that provision has come and gone), and to cap Medicare Part D costs at $2,000 per year for seniors.